Sun Pharma successfully removed an injunction in the US on the launch of its Leqselvi for alopecia areata, a common form of hair loss, that was sought by rival Incyte. The decision in the US Court ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. alopecia market with its JAK inhibitor Leqselvi, teeing up a potential showdown with ...

The case, Incyte v. Sun Pharmaceuticals, was filed in June 2024 over the alleged infringement of a patent on Leqselvi, a drug used to treat alopecia areata, an autoimmune disease that causes hair ...

Photograph: Francis Mascarenhas/Reuters Recent acquisitions, a favourable court ruling in the case of the hair loss drug ...

Sun Pharmaceutical Industries Ltd, which has been embroiled in a patent lawsuit in the US since last year over its specialty drug Leqselvi, received a favourable ruling from a court, paving the ...

Indian benchmark Nifty 50 spent the day in the green. Nifty opened at 24,070 and ended the day at 24,329 gaining 289 points. It regained Friday’s losses and saw high momentum today. Out of the total ...

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck ...

US Court vacates injunction, allowing Sun Pharma to launch Leqselvi Emkay Global suggests a royalty-based settlement with Incyte Leqselvi's US sales projected at $40 million in FY26, $124 million ...

The U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against the launch of LEQSELVI™ (deuruxolitinib) in the United States. Larsen & Toubro, HCL Technologies ...

4. Sun Pharma snags appeals win over Incyte, clearing way for US launch of alopecia med Leqselvi Sun Pharma can proceed with its launch of the alopecia therapy Leqselvi after a U.S. appeals court ...